NCT00092521 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 2723
- group Id
- BG001
- value
- 304
- group Id
- BG002
- value
- 2732
- group Id
- BG003
- value
- 5759
- units
- Participants
- groups
- description
- The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine. The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Quadrivalent HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.
- id
- BG000
- title
- Group 1 - Base Study Quadrivalent Human Papillomavirus Vaccine
- description
- The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with the Monovalent (HPV 16) HPV vaccine. The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Monovalent (HPV 16) HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.
- id
- BG001
- title
- Group 2 - Base Study Monovalent HPV (Type 16) Vaccine
- description
- The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 3 were vaccinated (at Day 1, Month 2 and Month 6) with placebo. The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo; from completion of the Vaccination Period at Month 7 through Month 48 of the study.
- id
- BG002
- title
- Group 3 - Base Study Placebo
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 1.8
- value
- 20.2
- group Id
- BG001
- spread
- 1.74
- value
- 20.2
- group Id
- BG002
- spread
- 1.8
- value
- 20.3
- group Id
- BG003
- spread
- 1.8
- value
- 20.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 16
- upper Limit
- 24
- value
- 20
- group Id
- BG001
- lower Limit
- 16
- upper Limit
- 24
- value
- 20
- group Id
- BG002
- lower Limit
- 16
- upper Limit
- 24
- value
- 20
- group Id
- BG003
- lower Limit
- 16
- upper Limit
- 24
- value
- 20
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2723
- group Id
- BG001
- value
- 304
- group Id
- BG002
- value
- 2732
- group Id
- BG003
- value
- 5759
- title
- 16 to 24 Years of Age
- description
- Although the upper age limit for this study was 23 years old, four subjects aged 24 were randomized into the study.
- param Type
- NUMBER
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2723
- group Id
- BG001
- value
- 304
- group Id
- BG002
- value
- 2732
- group Id
- BG003
- value
- 5759
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 151
- group Id
- BG001
- value
- 27
- group Id
- BG002
- value
- 165
- group Id
- BG003
- value
- 343
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 136
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 167
- group Id
- BG003
- value
- 308
- title
- Black
- categories
- measurements
- group Id
- BG000
- value
- 567
- group Id
- BG001
- value
- 93
- group Id
- BG002
- value
- 566
- group Id
- BG003
- value
- 1226
- title
- Hispanic American
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 22
- title
- Native American
- categories
- measurements
- group Id
- BG000
- value
- 1600
- group Id
- BG001
- value
- 171
- group Id
- BG002
- value
- 1558
- group Id
- BG003
- value
- 3329
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 259
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 266
- group Id
- BG003
- value
- 531
- title
- Other - Unspecified
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 2723
- group Id
- BG001
- value
- 304
- group Id
- BG002
- value
- 2732
- group Id
- BG003
- value
- 5759
- units
- Participants
- groups
- description
- The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine. The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Quadrivalent HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.
- id
- BG000
- title
- Group 1 - Base Study Quadrivalent Human Papillomavirus Vaccine
- description
- The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with the Monovalent (HPV 16) HPV vaccine. The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Monovalent (HPV 16) HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.
- id
- BG001
- title
- Group 2 - Base Study Monovalent HPV (Type 16) Vaccine
- description
- The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 3 were vaccinated (at Day 1, Month 2 and Month 6) with placebo. The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo; from completion of the Vaccination Period at Month 7 through Month 48 of the study.
- id
- BG002
- title
- Group 3 - Base Study Placebo
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 1.8
- value
- 20.2
- group Id
- BG001
- spread
- 1.74
- value
- 20.2
- group Id
- BG002
- spread
- 1.8
- value
- 20.3
- group Id
- BG003
- spread
- 1.8
- value
- 20.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 16
- upper Limit
- 24
- value
- 20
- group Id
- BG001
- lower Limit
- 16
- upper Limit
- 24
- value
- 20
- group Id
- BG002
- lower Limit
- 16
- upper Limit
- 24
- value
- 20
- group Id
- BG003
- lower Limit
- 16
- upper Limit
- 24
- value
- 20
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2723
- group Id
- BG001
- value
- 304
- group Id
- BG002
- value
- 2732
- group Id
- BG003
- value
- 5759
- title
- 16 to 24 Years of Age
- description
- Although the upper age limit for this study was 23 years old, four subjects aged 24 were randomized into the study.
- param Type
- NUMBER
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2723
- group Id
- BG001
- value
- 304
- group Id
- BG002
- value
- 2732
- group Id
- BG003
- value
- 5759
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 151
- group Id
- BG001
- value
- 27
- group Id
- BG002
- value
- 165
- group Id
- BG003
- value
- 343
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 136
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 167
- group Id
- BG003
- value
- 308
- title
- Black
- categories
- measurements
- group Id
- BG000
- value
- 567
- group Id
- BG001
- value
- 93
- group Id
- BG002
- value
- 566
- group Id
- BG003
- value
- 1226
- title
- Hispanic American
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 22
- title
- Native American
- categories
- measurements
- group Id
- BG000
- value
- 1600
- group Id
- BG001
- value
- 171
- group Id
- BG002
- value
- 1558
- group Id
- BG003
- value
- 3329
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 259
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 266
- group Id
- BG003
- value
- 531
- title
- Other - Unspecified
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle